Susan G. Komen has awarded $10.8 million in new research grants that will help propel innovative science and deliver hope to those facing breast cancer. The grant recipients include Department of Medicine faculty Drs. Tuya Pal (Genetic Medicine and Clinical Pharmacology) and Ben Ho Park (Hematology and Oncology).
According to a newly published study in the Annals of Internal Medicine by Andreana Holowatyj, PhD, MSCI (Hematology and Oncology), and colleagues, cases of appendiceal cancer tripled for Americans born between 1976 to 1984, and quadrupled for those born between 1981 and 1989.
Andreana Holowatyj, PhD, MSCI (Hematology and Oncology), has been named to the 40 Under 40 In Cancer Class of 2025 by the Association for Value-Based Cancer Care.
Three Department of Medicine faculty are among the 13 new members inducted into the AEE. They are: Lindsay Bischoff, MD (Diabetes, Endocrinology and Metabolism), Barbara Gisella Carranza Leon, MD (Diabetes, Endocrinology and Metabolism), Megan Dupuis, MD, PhD (Hematology and Oncology).
The cellular therapy programs at Vanderbilt-Ingram Cancer Center, Monroe Carell Jr. Children’s Hospital at Vanderbilt, and the VA Tennessee Valley Healthcare System have received reaccreditation from the Foundation for the Accreditation of Cellular Therapy (FACT).
Kimberly Dahlman, PhD, associate professor of Medicine in the Division of Hematology and Oncology, will begin serving her three-year term upon the closing of the association’s annual conference on June 17.
Research published in JAMA Dermatology by VUMC investigators, including senior corresponding author Douglas Johnson, MD, MSCI (Hematology and Oncology), provides insight into chronic cirAEs.
Faculty members Drs. Elizabeth Phillips (Infectious diseases) and Michael Savona (Hematology and Oncology) are among the six Vanderbilt University faculty members that have been elected fellows of the American Association for the Advancement of Science.
Adetola Kassim, MBBS (Hematology and Oncology), is co-first author of the paper that reported of 38 adults with severe SCD who participated in the study, more than 97% no longer required immunosuppressive therapy one year after the transplant.
